Phenotypic analysis of PBMCs from patients with CLL 24 hours after infection with MVA-TRICOM
Patient, PBMCs . | B7-1, % (MFI) . | ICAM-1, % (MFI) . | LFA-3, % (MFI) . |
|---|---|---|---|
| 1 | |||
| Uninfected | 0.9 (74) | 9.7 (25) | 61.1 (28) |
| MVA-TRICOM | 61.7 (753) | 76.9 (2310) | 88.1 (1047) |
| 2 | |||
| Uninfected | 1.0 (100) | 29.2 (71) | 21.6 (95) |
| MVA-TRICOM | 36.8 (1239) | 67.2 (3430) | 57.3 (1339) |
| 3 | |||
| Uninfected | 17.7 (7) | 83.2 (9) | 81.2 (24) |
| MVA-TRICOM | 44.5 (106) | 94.2 (134) | 85.1 (67) |
| 4 | |||
| Uninfected | 0.1 (31) | 39.0 (137) | 41.0 (118) |
| MVA-TRICOM | 10.5 (1384) | 45.5 (2318) | 44.4 (1053) |
| 5 | |||
| Uninfected | 0.7 (192) | 2.6 (118) | 13.4 (25) |
| MVA-TRICOM | 69.7 (243) | 67.2 (489) | 66.6 (216) |
| 6 | |||
| Uninfected | 10.7 (16) | 71.3 (23) | 96.3 (35) |
| MVA-TRICOM | 38.5 (383) | 79.4 (906) | 93.8 (351) |
| 7 | |||
| Uninfected | 52.1 (29) | 83.6 (35) | 97.2 (99) |
| MVA-TRICOM | 72.4 (277) | 92.2 (983) | 97.2 (406) |
| 8 | |||
| Uninfected | 0.1 (12) | 97.5 (58) | 66.0 (19) |
| MVA-TRICOM | 52.2 (348) | 98.5 (1038) | 89.2 (436) |
| 9 | |||
| Uninfected | 1.9 (53) | 18.3 (19) | 14.4 (16) |
| MVA-TRICOM | 40.3 (200) | 51.5 (506) | 52.9 (216) |
| 10 | |||
| Uninfected | 12.0 (22) | 19.9 (31) | 38.9 (30) |
| MVA-TRICOM | 64.3 (343) | 95.8 (1474) | 81.1 (539) |
| 11 | |||
| Uninfected | 18.1 (31) | 81.1 (62) | 48.4 (20) |
| MVA-TRICOM | 78.9 (261) | 97.1 (1321) | 87.3 (468) |
| 12 | |||
| Uninfected | 1.3 (141) | 75.6 (53) | 98.4 (62) |
| MVA-TRICOM | 92.6 (1052) | 98.6 (1387) | 99.9 (789) |
| 13 | |||
| Uninfected | 0.4 (134) | 78.7 (35) | 88.4 (34) |
| MVA-TRICOM | 87.5 (477) | 95.8 (952) | 96.7 (597) |
| 14 | |||
| Uninfected | 28.3 (135) | 77.8 (213) | 53.8 (96) |
| MVA-TRICOM | 84.9 (1113) | 91.9 (1974) | 95.9 (974) |
| 15 | |||
| Uninfected | 7.1 (58) | 37.2 (69) | 77.0 (69) |
| MVA-TRICOM | 57.9 (880) | 75.0 (2454) | 88.6 (1026) |
| 16 | |||
| Uninfected | 0.1 (116) | 5.1 (86) | 2.8 (98) |
| MVA-TRICOM | 39.3 (491) | 45.5 (1049) | 40.7 (500) |
| 17 | |||
| Uninfected | 0.7 (24) | 67.3 (26) | 98.7 (54) |
| MVA-TRICOM | 82.4 (1378) | 89.6 (1615) | 92.7 (865) |
| 18 | |||
| Uninfected | 0.7 (29) | 22.1 (82) | 90.5 (24) |
| MVA-TRICOM | 88.5 (601) | 86.9 (631) | 98.2 (330) |
| 19 | |||
| Uninfected | 0.3 (346) | 29.9 (47) | 31.6 (35) |
| MVA-TRICOM | 82.5 (407) | 68.4 (1062) | 92.3 (491) |
Patient, PBMCs . | B7-1, % (MFI) . | ICAM-1, % (MFI) . | LFA-3, % (MFI) . |
|---|---|---|---|
| 1 | |||
| Uninfected | 0.9 (74) | 9.7 (25) | 61.1 (28) |
| MVA-TRICOM | 61.7 (753) | 76.9 (2310) | 88.1 (1047) |
| 2 | |||
| Uninfected | 1.0 (100) | 29.2 (71) | 21.6 (95) |
| MVA-TRICOM | 36.8 (1239) | 67.2 (3430) | 57.3 (1339) |
| 3 | |||
| Uninfected | 17.7 (7) | 83.2 (9) | 81.2 (24) |
| MVA-TRICOM | 44.5 (106) | 94.2 (134) | 85.1 (67) |
| 4 | |||
| Uninfected | 0.1 (31) | 39.0 (137) | 41.0 (118) |
| MVA-TRICOM | 10.5 (1384) | 45.5 (2318) | 44.4 (1053) |
| 5 | |||
| Uninfected | 0.7 (192) | 2.6 (118) | 13.4 (25) |
| MVA-TRICOM | 69.7 (243) | 67.2 (489) | 66.6 (216) |
| 6 | |||
| Uninfected | 10.7 (16) | 71.3 (23) | 96.3 (35) |
| MVA-TRICOM | 38.5 (383) | 79.4 (906) | 93.8 (351) |
| 7 | |||
| Uninfected | 52.1 (29) | 83.6 (35) | 97.2 (99) |
| MVA-TRICOM | 72.4 (277) | 92.2 (983) | 97.2 (406) |
| 8 | |||
| Uninfected | 0.1 (12) | 97.5 (58) | 66.0 (19) |
| MVA-TRICOM | 52.2 (348) | 98.5 (1038) | 89.2 (436) |
| 9 | |||
| Uninfected | 1.9 (53) | 18.3 (19) | 14.4 (16) |
| MVA-TRICOM | 40.3 (200) | 51.5 (506) | 52.9 (216) |
| 10 | |||
| Uninfected | 12.0 (22) | 19.9 (31) | 38.9 (30) |
| MVA-TRICOM | 64.3 (343) | 95.8 (1474) | 81.1 (539) |
| 11 | |||
| Uninfected | 18.1 (31) | 81.1 (62) | 48.4 (20) |
| MVA-TRICOM | 78.9 (261) | 97.1 (1321) | 87.3 (468) |
| 12 | |||
| Uninfected | 1.3 (141) | 75.6 (53) | 98.4 (62) |
| MVA-TRICOM | 92.6 (1052) | 98.6 (1387) | 99.9 (789) |
| 13 | |||
| Uninfected | 0.4 (134) | 78.7 (35) | 88.4 (34) |
| MVA-TRICOM | 87.5 (477) | 95.8 (952) | 96.7 (597) |
| 14 | |||
| Uninfected | 28.3 (135) | 77.8 (213) | 53.8 (96) |
| MVA-TRICOM | 84.9 (1113) | 91.9 (1974) | 95.9 (974) |
| 15 | |||
| Uninfected | 7.1 (58) | 37.2 (69) | 77.0 (69) |
| MVA-TRICOM | 57.9 (880) | 75.0 (2454) | 88.6 (1026) |
| 16 | |||
| Uninfected | 0.1 (116) | 5.1 (86) | 2.8 (98) |
| MVA-TRICOM | 39.3 (491) | 45.5 (1049) | 40.7 (500) |
| 17 | |||
| Uninfected | 0.7 (24) | 67.3 (26) | 98.7 (54) |
| MVA-TRICOM | 82.4 (1378) | 89.6 (1615) | 92.7 (865) |
| 18 | |||
| Uninfected | 0.7 (29) | 22.1 (82) | 90.5 (24) |
| MVA-TRICOM | 88.5 (601) | 86.9 (631) | 98.2 (330) |
| 19 | |||
| Uninfected | 0.3 (346) | 29.9 (47) | 31.6 (35) |
| MVA-TRICOM | 82.5 (407) | 68.4 (1062) | 92.3 (491) |
Percentages indicate positive cells for CD19 and B7-1, ICAM-1, or LFA-3; MFI values are for the expression of each costimulatory molecule. There were no changes in B7-1, ICAM-1, and LFA-3 expression in CLL cells from the above 19 patients when infected with wild-type MVA-WT vector.